"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
Below are MeSH descriptors whose meaning is more general than "Androstenes".
Below are MeSH descriptors whose meaning is more specific than "Androstenes".
This graph shows the total number of publications written about "Androstenes" by people in Harvard Catalyst Profiles by year, and whether "Androstenes" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2003 | 1 | 2 | 3 |
2006 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2008 | 4 | 0 | 4 |
2009 | 3 | 1 | 4 |
2010 | 0 | 2 | 2 |
2011 | 0 | 4 | 4 |
2012 | 0 | 1 | 1 |
2013 | 2 | 3 | 5 |
2014 | 4 | 5 | 9 |
2015 | 2 | 1 | 3 |
2016 | 4 | 2 | 6 |
2017 | 3 | 4 | 7 |
2018 | 3 | 5 | 8 |
2019 | 5 | 3 | 8 |
2020 | 2 | 3 | 5 |
2021 | 3 | 5 | 8 |
2022 | 0 | 5 | 5 |
Below are the most recent publications written about "Androstenes" by people in Profiles.
-
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer. J Natl Compr Canc Netw. 2022 10; 20(10):1107-1115.e12.
-
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. J Natl Cancer Inst. 2022 08 08; 114(8):1127-1134.
-
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations. J Natl Cancer Inst. 2022 08 08; 114(8):1057-1058.
-
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. JNCI Cancer Spectr. 2022 03 02; 6(2).
-
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar; 18(10):1185-1198.
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
-
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2022 03 10; 40(8):825-836.
-
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 11 01; 27(21):6001-6011.
-
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clin Genitourin Cancer. 2021 12; 19(6):480-490.
-
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021 07 10; 398(10295):131-142.